The most effective and promising population health strategies to advance human papillomavirus vaccination

Expert Review of Vaccines

Volumn 15, Issue 2, 2016, Pages 257-269

  Jacobson, Robert M ^a   Agunwamba, Amenah A ^a   St Sauver, Jennifer L ^a   Rutten, Lila J Finney ^a  

^a MAYO CLINIC   (United States)

Author keywords

adolescent; child; health knowledge, attitudes, practice; immunization; immunization programs; Papillomavirus vaccines; United States; vaccination

Indexed keywords

WART VIRUS VACCINE;

CHILD; COMMUNICATION SKILL; DRUG TREATMENT FAILURE; DRUG UPTAKE; FEEDBACK SYSTEM; HEALTH CARE NEED; HEALTH EDUCATION; HERD IMMUNITY; HOSPITAL INFORMATION SYSTEM; HUMAN; MEDICAL AUDIT; NURSING PROTOCOL; PAPILLOMAVIRUS INFECTION; PEDIATRICS; POLITICS; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMINDER SYSTEM; REVIEW; SAFETY; SEXUAL MATURITY; SYSTEMATIC REVIEW (TOPIC); TIME; VACCINATION; ATTITUDE TO HEALTH; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PSYCHOLOGY; UTILIZATION;

HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 84955648388     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1116947     Document Type: Review

References (120)

1. Papers of special note have been highlighted as
2. of interest
3. of considerable interest
4. Healthy People 2020. Immunization and infectious diseases 2020 Topics & Objectives. 2015 [ cited 2015 Jul 31 ]. Available from: http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-And-infectious-diseases/objectives
5. Reagan-Steiner S, Yankey D, Jeyarajah J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015 Jul 31; 64 (29): 784-792
6. Markowitz LE, Dunne EF, Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23; 56 (RR-2): 1-24
7. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28; 59 (20): 630-632
8. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011 Dec 23; 60 (50): 1705-1708
9. Jeudin P, Liveright E, Del Carmen MG., et al. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin Ther. 2014 Jan 1; 36 (1): 24-37
10. Hofstetter AM, Rosenthal SL. Factors impacting HPV vaccination: lessons for health care professionals. Expert Rev Vaccines. 2014 Aug; 13 (8): 1013-1026
11. Markowitz LE, Tsu V, Deeks SL., et al. Human papillomavirus vaccine introduction-The first five years. Vaccine. 2012 Nov 20; 30 (Suppl 5): F139-48
12. Nordin JD, Solberg LI, Parker ED. Adolescent primary care visit patterns. Ann Fam Med. 2010 Nov-Dec; 8 (6): 511-516
13. Committee on Practice and Ambulatory Medicine, Bright Futures Periodicity Schedule Workgroup. 2014 recommendations for pediatric preventive health care. Pediatrics. 2014 Mar 1; 133 (3): 568-570
14. Alderman EM. AMA guidelines for adolescent preventive services (GAPS): recommendations and rationale. JAMA. 1994; 272 (12): 980-981
15. Wong CA, Taylor JA, Wright JA., et al. Missed opportunities for adolescent vaccination, 2006-2011. J Adolesc Health. 2013; 53 (4): 492-497
16. Kahn JA, Zimet GD, Bernstein DI., et al. Pediatricians intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005; 37 (6): 502-510
17. Dorell C, Yankey D, Strasser S. Parent-reported reasons for nonreceipt of recommended adolescent vaccinations, National Immunization Survey: teen, 2009. Clin Pediatr (Phila). 2011 Dec; 50 (12): 1116-1124
18. Trim K, Nagji N, Elit L., et al. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstet Gynecol Int. 2012; 2012: 921236
19. Joseph N, Clark J, Bauchner H., et al. Knowledge, attitudes, and beliefs regarding HPV vaccination: ethnic and cultural differences between African-American and Haitian immigrant women. Womens Health Issues. 2012 Nov-Dec; 22 (6): e571-579. 10.1016/j.whi.2012.09.003
20. Darden PM, Thompson DM, Roberts JR., et al. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics. 2013; 131 (4): 645-651
21. Jacobson RM, Roberts JR, Darden PM. Parents perceptions of the HPV vaccine: a key target for improving immunization rates. Expert Rev Clin Immunol. 2013 Sep; 9 (9): 791-793
22. Patel PR, Berenson AB. Sources of HPV vaccine hesitancy in parents. Hum Vaccin Immunother. 2013 Dec; 9 (12): 2649-2653
23. Holman DM, Benard V, Roland KB., et al. Barriers to human papillomavirus vaccination among US adolescents a systematic review of the literature. JAMA Pediatrics. 2014; 168 (1): 76-82
24. Lo B. HPV vaccine and adolescents sexual activity-It would be a shame if unresolved ethical dilemmas hampered this breakthrough. Brit Med J. 2006; 332 (7550): 1106-1107
25. Charo RA. Politics, parents, and prophylaxis-mandating HPV vaccination in the United States. N Engl J Med. 2007; 356 (19): 1905-1908
26. Ferrer HB, Trotter C, Hickman M., et al. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014. 10.1186/1471-2458-14-700. Article number: 700
27. Ogilvie G, Anderson M, Marra F., et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010; 7 (5): e1000270
28. Kester LM, Zimet GD, Fortenberry JD., et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J. 2013; 17 (5): 879-885
29. Perkins RB, Clark JA, Apte G., et al. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics. 2014; 134 (3): e666-674
30. Olshen E, Mahon BE, Wang S., et al. The impact of state policies on vaccine coverage by age 13 in an insured population. J Adolesc Health. 2007; 40 (5): 405-411
31. Feikin DR, Lezotte DC, Hamman RF., et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA. 2000 Dec 27; 284 (24): 3145-3150
32. Omer SB, Pan WK, Halsey NA., et al. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA. 2006 Oct 11; 296 (14): 1757-1763
33. Omer SB, Enger KS, Moulton LH., et al. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol. 2008 Dec 15; 168 (12): 1389-1396
34. Schwartz JL, Easterling LA. State vaccination requirements for HPV and other vaccines for adolescents, 1990-2015. JAMA. 2015 Jul 14; 314 (2): 185-186
35. National Conference of State Legislatures. HPV Vaccine Policies. Health Care. 2015 [ cited 2015 Aug 6 ]. Available from: http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-And-statutes.aspx
36. Schwartz JL, Caplan AL, Faden RR., et al. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther. 2007; 82 (6): 760-763
37. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010 May 28; 59 (20): 626-629
38. Centers for Disease Control and Prevention. HPV vaccine-questions & answers. Vaccines and Immunizations. 2015 Jun 30 [ cited 2015 Aug 6 ]. Available from: http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm
39. Mast EE, Weinbaum CM, Fiore AE., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006 Dec 8; 55 (RR-16): 1-33. quiz CE1-4
40. Mast EE, Margolis HS, Fiore AE., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005 Dec 23; 54 (RR-16): 1-31
41. Fiore AE, Shay DK, Broder K., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009 Jul 31; 58 (RR-8): 1-52
42. Advisory Committee on Immunization Practices. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999; 48 (RR-7): 1-17, 21-25
43. Poland GA. Vaccines against Lyme disease: what happened and what lessons can we learn? Clin Infect Dis. 2011 Feb; 52 (Suppl 3): S253-258
44. Frieden T. Protect the next generation: recommend the HPV vaccine. CDC Expert Commentary. 2014 [ cited 2015 Sep 10 ]. Available from: http://www.medscape.com/viewarticle/829938
45. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24 (Suppl 1): S1-15
46. Ho GY, Bierman R, Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12; 338 (7): 423-428
47. Woodman CB, Collins S, Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001 Jun 9; 357 (9271): 1831-1836
48. Winer RL, Lee SK, Hughes JP., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003 Feb 1; 157 (3): 218-226
49. Molano M, Van Den Brule A, Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003 Sep 1; 158 (5): 486-494
50. Dunne EF, Markowitz LE, Saraiya M., et al. CDC grand rounds: reducing the burden of HPV-Associated cancer and disease. MMWR Morb Mortal Wkly Rep. 2014 Jan 31; 63 (4): 69-72
51. Basu P, Banerjee D, Singh P., et al. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: a review of evidence from phase III trials and national programs. South Asian J Cancer. 2013; 2 (4): 187-192
52. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 (Suppl 5): F123-138
53. Klein NP, Hansen J, Chao C., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012; 166 (12): 1140-1148
54. Chao C, Klein NP, Velicer CM., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012; 271 (2): 193-203
55. Vichnin M, Bonanni P, Klein NP., et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J. 2015; 34 (9): 983-991
56. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf. 2015 May; 14 (5): 697-712
57. Vesikari T, Brodszki N, van Damme P., et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil(R) in 9-15-year-old girls. Pediatr Infect Dis J. 2015; 34 (9): 992-998
58. Petrosky E, Bocchini JA, Hariri S., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. Mmwr-Morbid Mortal W. 2015 Mar 27; 64 (11): 300-304
59. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369 (9576): 1861-1868
60. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb; 36 (1): 6-10
61. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat. 2011;23(31):1-35
62. Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012 Jan; 42 (1): 44-52
63. Bednarczyk RA, Davis R, Ault K., et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11-To 12-year-olds. Pediatrics. 2012; 130 (5): 798-805
64. Jena AB, Goldman DP, Seabury SA. Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females. JAMA Intern Med. 2015 Apr; 175 (4): 617-623
65. Smith LM, Kaufman JS, Strumpf EC., et al. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. Can Med Assoc J. 2015 Feb 3; 187 (2): E74-E81
66. Opel DJ, Heritage J, Taylor JA., et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013; 132 (6): 1037-1046
67. Opel DJ, Mangione-Smith R, Robinson JD., et al. The influence of provider communication behaviors on parental vaccine acceptance and visit experience. Am J Prev Med. 2015;105(10):1998-2004
68. Rosenthal SL, Weiss TW, Zimet GD., et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physicians recommendation. Vaccine. 2011 Jan 29; 29 (5): 890-895
69. Henrikson NB, Opel DJ, Grothaus L., et al. Physician communication training and parental vaccine hesitancy: a randomized trial. Pediatrics. 2015 Jul; 136 (1):70-79
70. Leask J, Kinnersley P. Physician communication with vaccine-hesitant parents: the start, not the end, of the story. Pediatrics. 2015;136(1):180-182
71. Nyhan B, Reifler J, Richey S., et al. Effective messages in vaccine promotion: a randomized trial. Pediatrics. 2014; 133 (4): e835-842
72. Nyhan B, Reifler J. Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information. Vaccine. 2015; 33 (3): 459-464
73. Nyhan B, Reifler J. When corrections fail: the persistence of political misperceptions. Polit Behav. 2010; 32 (2): 303-330
74. Horne Z, Powell D, Hummel JE., et al. Countering antivaccination attitudes. Proc Natl Acad Sci. 2015;112(33):10321-10324
75. Fu LY, Bonhomme L-A, Cooper SC., et al. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine. 2014; 32 (17): 1901-1920
76. Sherris J, Friedman A, Wittet S., et al. Chapter 25: Education, training, and communication for HPV vaccines. Vaccine. 2006 Aug 31; 24 (Suppl 3): S3/210-218
77. Niccolai LM, Hansen CE. Practice-And community-based interventions to increase human papillomavirus vaccine coverage: a systematic review. JAMA Pediatrics. 2015; 169 (7): 686-692
78. Briss PA, Rodewald LE, Hinman AR., et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults: the task force on community preventive services. Am J Prev Med. 2000; 18 (1 Suppl): 97-140
79. Kharbanda EO, Stockwell MS, Fox HW., et al. Text message reminders to promote human papillomavirus vaccination. Vaccine. 2011 Mar 21; 29 (14): 2537-2541
80. Szilagyi PG, Humiston SG, Gallivan S., et al. Effectiveness of a citywide patient immunization navigator program on improving adolescent immunizations and preventive care visit rates. Arch Pediatr Adolesc Med. 2011 Jun; 165 (6): 547-553
81. Suh CA, Saville A, Daley MF., et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics. 2012; 129 (6): e1437-1445
82. Fiks AG, Grundmeier RW, Mayne S., et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013; 131 (6): 1114-1124
83. Szilagyi PG, Albertin C, Humiston SG., et al. A randomized trial of the effect of centralized reminder/recall on immunizations and preventive care visits for adolescents. Acad Pediatr. 2013; 13 (3): 204-213
84. Cassidy B, Braxter B, Charron-Prochownik D., et al. A quality improvement initiative to increase HPV vaccine rates using an educational and reminder strategy with parents of preteen girls. J Pediatr Health Car. 2014; 28 (2): 155-164
85. Matheson EC, Derouin A, Gagliano M., et al. Increasing HPV vaccination series completion rates via text message reminders. J Pediatr Health Car. 2014; 28 (4): E35-E39
86. Nettleman MD, Garcia-Chen V. Vaccinating through a lifetime: adult priorities [Internet]. South Dakota Med. Special Edition 2013. Chapter 11. p. 73-79. [cited 2015 Nov 21] Available from: https://www.sdsma.org/docs/pdfs-new-site/Journal/2013/SDMSpecial%20Issue2013l.pdf
87. Elam-Evans LD, Yankey D, Jeyarajah J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2013. MMWR Morb Mortal Wkly Rep. 2014 Jul 25; 63 (29): 625-633
88. Dempsey AF, Pyrzanowski J, Brewer S., et al. Acceptability of using standing orders to deliver human papillomavirus vaccines in the outpatient obstetrician/gynecologist setting. Vaccine. 2015 Apr 8; 33 (15): 1773-1779
89. Bundy DG, Persing NM, Solomon BS., et al. Improving immunization delivery using an electronic health record: the ImmProve Project. Acad Pediatr. 2013; 13 (5): 458-465
90. Moss JL, Reiter PL, Dayton A., et al. Increasing adolescent immunization by webinar: a brief provider intervention at federally qualified health centers. Vaccine. 2012 Jul 13; 30 (33): 4960-4963
91. Gilkey MB, Dayton AM, Moss JL., et al. Increasing provision of adolescent vaccines in primary care: a randomized controlled trial. Pediatrics. 2014; 134 (2): e346-353
92. Shah PD, Gilkey MB, Pepper JK., et al. Promising alternative settings for HPV vaccination of US adolescents. Expert Rev Vaccines. 2014; 13 (2): 235-246
93. Ladner J, Besson MH, Rodrigues M., et al. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health. 2014; 14: 670
94. World Health Organization. HPV vaccination. In: Comprehensive cervical cancer control: a guide to essential practice (C4 GEP). 2nd ed. Geneva: World Health Organization; 2014. p. 30
95. Community Preventive Services Task Force. Increasing appropriate vaccination: vaccination programs in schools and organized child care centers. Guide to Community Preventive Services. 2014 Jun 3 [ cited 2015 Sep 2 ]. Available from: http://www.thecommunityguide.org/vaccines/schools-childcare.html
96. Kwong JC, Ge H, Rosella LC., et al. School-based influenza vaccine delivery, vaccination rates, and healthcare use in the context of a universal influenza immunization program: an ecological study. Vaccine. 2010 Mar 24; 28 (15): 2722-2729
97. Wilson SE, Harris T, Sethi P., et al. Coverage from Ontario, Canadas school-based HPV vaccine program: the first three years. Vaccine. 2013 Jan 21; 31 (5): 757-762
98. McClure CA, MacSwain MA, Morrison H., et al. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada. Vaccine. 2015 Apr 8; 33 (15): 1786-1790
99. Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. DataParliamentUK. 2010 Dec 22 [ cited 2015 Sep 2 ]. Available from: http://data.parliament.uk/DepositedPapers/Files/DEP2012-1386/PQ119371-2.pdf
100. Fregnani JH, Carvalho AL, Eluf-Neto J., et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013; 8 (4): e62647
101. Binagwaho A, Wagner CM, Gatera M., et al. Achieving high coverage in Rwandas national human papillomavirus vaccination programme. Bull World Health Organ. 2012 Aug 1; 90 (8): 623-628
102. Watson M, Shaw D, Molchanoff L., et al. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health. 2009; 33 (4): 365-370
103. Bernard DM, Cooper Robbins SC, McCaffery KJ., et al. The domino effect: adolescent girls response to human papillomavirus vaccination. Med J Aust. 2011 Mar 21; 194 (6): 297-300
104. Humiston SG, Poehling KA, Szilagyi PG. School-located influenza vaccination: can collaborative efforts go the distance? Acad Pediatr. 2014 May-Jun; 14 (3): 219-220
105. Kempe A, Daley MF, Pyrzanowski J., et al. School-located influenza vaccination with third-party billing: what do parents think? Acad Pediatr. 2014; 14 (3): 241-248
106. Kempe A, Daley MF, Pyrzanowski J., et al. School-located influenza vaccination with third-party billing: outcomes, cost, and reimbursement. Acad Pediatr. 2014; 14 (3): 234-240
107. Stubbs BW, Panozzo CA, Moss JL., et al. Evaluation of an intervention providing HPV vaccine in schools. Am J Health Behav. 2014; 38 (1): 92-102
108. Kelminson K, Saville A, Seewald L., et al. Parental views of school-located delivery of adolescent vaccines. J Adolesc Health. 2012; 51 (2): 190-196
109. Venkatesh SR, Acosta AB, Middleman AB. Private middle school parents perspectives regarding school-located immunization programs (SLIPs). J Sch Nurs. 2013 Aug; 29 (4): 315-319
110. Gargano LM, Weiss P, Underwood NL., et al. School-located vaccination clinics for adolescents: correlates of acceptance among parents. J Community Health. 2015; 40 (4): 660-669
111. Hayes KA, Entzel P, Berger W., et al. Early lessons learned from extramural school programs that offer HPV vaccine. J Sch Health. 2013; 83 (2): 119-126
112. Daley MF, Kempe A, Pyrzanowski J., et al. School-located vaccination of adolescents with insurance billing: cost, reimbursement, and vaccination outcomes. J Adolescent Health: Official Publication Soc Adolesc Med. 2014; 54 (3): 282-288
113. Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health vs private wealth. JAMA. 2007; 297 (17): 1921-1923
114. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med. 2006; 355 (23): 2389-2391
115. Naifeh M, Ang S, Darden PM. Provider recommendation of HPV vaccine: how much difference does it make nationally and in Oklahoma? J Invest Med. 2011 Feb; 59 (2): 474
116. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health. 2013 Jan; 103 (1): 164-169
117. Darden PM, Jacobson RM. Impact of a physician recommendation. Hum Vaccin Immunother. 2014 Sep; 10 (9): 2632-2635
118. Jacobson RM. Making the C.A.S.E. for the human papillomavirus vaccine: how to talk to parents and adolescents. Minn Med. 2014 Feb; 97 (2): 38-42
119. Jacobson RM, Van Etta L, Bahta L. The C.A.S.E. approach: guidance for talking to vaccine-hesitant parents. Minn Med. 2013 Apr; 96 (4): 49-50
120. The HPV vaccine: Access and use in the US Womens Health Policy http://kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-Access-And-use-in/ The Henry J. Kaiser Family Foundation. Feb 26 [ cited 2015 Sep 2 ]. Available from.